Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Alliance Pharmaceuticals Limited, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, United Kingdom
Variquel 0.2 mg/ml, solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. Clear colourless aqueous solution with a pH of 5.7–6.3 and an osmolality of 270-330 mOsm/kg. |
Each 5 ml of injection solution contains 1 mg terlipressin acetate corresponding to 0.85 mg terlipressin.
Each ml contains 0.2 mg terlipressin acetate corresponding to 0.17 mg terlipressin.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Terlipressin |
Terlipressin inhibits portal hypertension with simultaneous reduction of blood circulation in portal vessels. Terlipressin contracts smooth oesophageal muscle with consecutive compression of oesophageal varices. |
| List of Excipients |
|---|
|
Glacial acetic acid |
Colourless glass type I vials, closed with bromobutyl rubber stopper and sealed with aluminium flip-off cap (green).
Each vial contains 5 ml of solution.
Pack sizes: 5 × 5ml.
Alliance Pharmaceuticals Limited, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB, United Kingdom
PL 16853/0149
18/10/2013
| Drug | Countries | |
|---|---|---|
| VARIQUEL | Ireland, Malta, New Zealand, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
